Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

June 30, 2010

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

AST-120

oral, sachet, 2 grams three times daily for 8 weeks

DRUG

Celphere® CP-305

oral, placebo, sachet, 2 grams three times daily for 8 weeks

Trial Locations (17)

1200

UCL St. Luc, Woluwe

3000

UZ Leuven, Leuven

3600

Zuid-Oost Limburg Campus St. Jan, Genk

8310

AZ St. Lucas Assebroek, Assebroek

11023

Long Island Gastrointestinal Research Group, Great Neck

20815

Chevy Chase Clinical Research, Chevy Chase

21401

Michael Epstein, MD, Annapolis

27262

Peters Medical Research, LLC, High Point

27403

LeBauer Research Associates, Greensboro

33436

Madeleine DuPree, MD, Boynton Beach

35801

Clinical Research Associates, Huntsville

45219

Ohio Gastroenterology and Liver Institute, Cincinnatti

53215

Wisconsin Center for Advanced Research, Milwaukee

73104

Oklahoma Foundation for Digestive Disease, Oklahoma City

77024

Breco Research LTD, Houston

92108

Medical Center for Clinical Research, San Diego

95821

Northern California Research, Sacramento

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ocera Therapeutics

INDUSTRY

NCT00583128 - Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter